A
$ Value
—
Shares
23,568
Price
—
Filed
Sep 3
Insider
Name
Zindrick Thomas
Title
President and CEO
CIK
0001937573
Roles
Director
Officer
Transaction Details
Transaction Date
2025-09-01
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
23,568
Footnotes
The shares subject to these options are fully vested. | The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. | The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
Filing Info
Zindrick Thomas's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-24 | GNLX | ▼ | $9K |
| 2025-11-17 | GNLX | ▼ | $24K |
| 2025-09-01 | GNLX | D | — |
| 2025-09-01 | GNLX | A | — |
| 2025-09-01 | GNLX | D | — |
| 2025-09-01 | GNLX | A | — |
| 2025-09-01 | GNLX | D | — |
| 2025-09-01 | GNLX | A | — |
| 2025-09-01 | GNLX | D | — |
| 2025-09-01 | GNLX | A | — |
Other Insiders at GNLX (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Yu Yong / Cappello Joseph
SVP, Clinical Development
|
— | $2K | 2026-03-24 |
|
Zindrick Thomas
President and CEO
|
— | $9K | 2026-03-24 |
| Thomas John | — | $29K | 2026-03-02 |
|
Smalling Ralph
Head of Regulatory
|
— | $1K | 2026-03-25 |